Alan C. Hunter

List of Publications by Year
in descending order

52	7,059	168829	206121
papers	citations	31 h-index	51 g-index

52	52	52	10843
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Interplay Between Blood Proteins, Complement, and Macrophages on Nanomedicine Performance and Responses. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 581-592.	1.3	47
2	Smart polymers in drug delivery: a biological perspective. Polymer Chemistry, 2017, 8, 41-51.	1.9	55
3	Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes. Nature Nanotechnology, 2017, 12, 589-594.	15.6	154
4	Quartz Crystal Microbalance Assay of Clinical Calcinosis Samples and Their Synthetic Models Differentiates the Efficacy of Chelation-Based Treatments. ACS Applied Materials & Interfaces, 2017, 9, 27544-27552.	4.0	5
5	AFM visualization of sub-50 nm polyplex disposition to the nuclear pore complex without compromising the integrity of the nuclear envelope. Journal of Controlled Release, 2016, 244, 24-29.	4.8	16
6	Platelet mimicry: The emperor's new clothes?. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 245-248.	1.7	19
7	Complement monitoring of Pluronic 127 gel and micelles: Suppression of copolymer-mediated complement activation by elevated serum levels of HDL, LDL, and apolipoproteins AI and B-100. Journal of Controlled Release, 2013, 170, 167-174.	4.8	43
8	Surfactant-mediated complement activation in beagle dogs. International Immunopharmacology, 2013, 17, 33-34.	1.7	7
9	Single-Walled Carbon Nanotube Surface Control of Complement Recognition and Activation. ACS Nano, 2013, 7, 1108-1119.	7.3	110
10	Complement activation by PEG-functionalized multi-walled carbon nanotubes is independent of PEG molecular mass and surface density. Nanomedicine: Nanotechnology, Biology, and Medicine, 2013, 9, 469-473.	1.7	38
11	Particulate Systems for Targeting of Macrophages: Basic and Therapeutic Concepts. Journal of Innate Immunity, 2012, 4, 509-528.	1.8	66
12	Polyethylenimine-mediated impairment of mitochondrial membrane potential, respiration and membrane integrity: Implications for nucleic acid delivery and gene therapy. Mitochondrion, 2012, 12, 162-168.	1.6	46
13	Genomic perspectives in inter-individual adverse responses following nanomedicine administration: The way forward. Advanced Drug Delivery Reviews, 2012, 64, 1385-1393.	6.6	44
14	Polymeric particulate technologies for oral drug delivery and targeting: A pathophysiological perspective. Maturitas, 2012, 73, 5-18.	1.0	34
15	Factors Controlling Nanoparticle Pharmacokinetics: An Integrated Analysis and Perspective. Annual Review of Pharmacology and Toxicology, 2012, 52, 481-503.	4.2	477
16	Complement system and the brain: Selected pathologies and avenues toward engineering of neurological nanomedicines. Journal of Controlled Release, 2012, 161, 283-289.	4.8	24
17	Transformation of structurally diverse steroidal analogues by the fungus Corynespora cassiicola CBS 161.60 results in generation of 8Î²-monohydroxylated metabolites with evidence in favour of 8Î²-hydroxylation through inverted binding in the 9Î±-hydroxylase. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2011, 1811, 1054-1061.	1.2	12
18	Material properties in complement activation. Advanced Drug Delivery Reviews, 2011, 63, 1000-1007.	6.6	230

#	Article	IF	Citations
19	Complement activation cascade triggered by PEGâ€“PL engineered nanomedicines and carbon nanotubes: The challenges ahead. Journal of Controlled Release, 2010, 146, 175-181.	4.8	157
20	Cationic carriers of genetic material and cell death: A mitochondrial tale. Biochimica Et Biophysica Acta - Bioenergetics, 2010, 1797, 1203-1209.	0.5	117
21	Polycation cytotoxicity: a delicate matter for nucleic acid therapyâ€”focus on polyethylenimine. Soft Matter, 2010, 6, 4001.	1.2	193
22	Distinct Polymer Architecture Mediates Switching of Complement Activation Pathways at the Nanosphereâ^'Serum Interface: Implications for Stealth Nanoparticle Engineering. ACS Nano, 2010, 4, 6629-6638.	7.3	263
23	Transformation of some 3Î±-substituted steroids by Aspergillus tamarii KITA reveals stereochemical restriction of steroid binding orientation in the minor hydroxylation pathway. Journal of Steroid Biochemistry and Molecular Biology, 2010, 118, 171-176.	1.2	19
24	Transformation of a series of saturated isomeric steroidal diols by Aspergillus tamarii KITA reveals a precise stereochemical requirement for entrance into the lactonization pathway. Journal of Steroid Biochemistry and Molecular Biology, 2010, 122, 352-358.	1.2	12
25	Application of the Quartz Crystal Microbalance to Nanomedicine. Journal of Biomedical Nanotechnology, 2009, 5, 669-675.	0.5	30
26	Transformation of 5-ene steroids by the fungus Aspergillus tamarii KITA: Mixed molecular fate in lactonization and hydroxylation pathways with identification of a putative 3Î²-hydroxy-steroid dehydrogenase/Î”5â€“Î”4 isomerase pathway. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2009, 1791, 110-117.	1.2	45
27	An unusual ringâ€”A opening and other reactions in steroid transformation by the thermophilic fungus Myceliophthora thermophila. Journal of Steroid Biochemistry and Molecular Biology, 2009, 116, 171-177.	1.2	28
28	Complement: Alive and Kicking Nanomedicines. Journal of Biomedical Nanotechnology, 2009, 5, 364-372.	0.5	71
29	Novel quartz crystal microbalance based biosensor for detection of oral epithelial cellâ€“microparticle interaction in real-time. Biosensors and Bioelectronics, 2008, 23, 1259-1265.	5.3	28
30	Predominant allylic hydroxylation at carbons 6 and 7 of 4 and 5-ene functionalized steroids by the thermophilic fungus Rhizomucor tauricus IMI23312. Journal of Steroid Biochemistry and Molecular Biology, 2008, 108, 155-163.	1.2	26
31	Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. Molecular Immunology, 2008, 45, 3797-3803.	1.0	122
32	Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Molecular Immunology, 2008, 46, 225-232.	1.0	231
33	Distinct metabolic handling of 3Î²-hydroxy-17a-oxa-D-homo-5Î±-androstan-17-one by the filamentous fungus Aspergillus tamarii KITA: Evidence in support of steroid/hydroxylase binding hypothesis. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2007, 1771, 1254-1261.	1.2	17
34	Ordering of Binary Polymeric Nanoparticles on Hydrophobic Surfaces Assembled from Low Volume Fraction Dispersions. Journal of the American Chemical Society, 2007, 129, 13390-13391.	6.6	36
35	Modification of the Stewart biphasic colorimetric assay for stable and accurate quantitatitive determination of Pluronic and Tetronic block copolymers for application in biological systems. Analytical Biochemistry, 2007, 361, 287-293.	1.1	21
36	Ring-B functionalized androst-4-en-3-ones and ring-C substituted pregn-4-en-3-ones undergo differential transformation in Aspergillus tamarii KITA: Ring-A transformation with all C-6 substituted steroids and ring-D transformation with C-11 substituents. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2006, 1761, 360-366.	1.2	24

#	Article	IF	Citations
37	An efficient one-pot synthesis generating 4-ene-3,6-dione functionalised steroids from steroidal 5-en-3Î²-ols using a modified Jones oxidation methodology. Steroids, 2006, 71, 30-33.	0.8	25
38	Concentration Dependent Structural Ordering of Poloxamine 908 on Polystyrene Nanoparticles and Their Modulatory Role on Complement Consumption. Journal of Nanoscience and Nanotechnology, 2006, 6, 3126-3133.	0.9	58
39	Activation of the Human Complement System by Cholesterol-Rich and PEGylated Liposomesâ€"Modulation of Cholesterol-Rich Liposome-Mediated Complement Activation by Elevated Serum LDL and HDL Levels. Journal of Liposome Research, 2006, 16, 167-174.	1.5	61
40	Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicityâ†. Advanced Drug Delivery Reviews, 2006, 58, 1523-1531.	6.6	424
41	A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. Molecular Therapy, 2005, 11, 990-995.	3.7	967
42	Fate of novel Quasi reverse steroidal substrates by Aspergillus tamarii KITA: Bypass of lactonisation and an exclusive role for the minor hydroxylation pathway. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2005, 1734, 190-197.	1.2	14
43	Low and high molecular weight poly(l-lysine)s/poly(l-lysine)-DNA complexes initiate mitochondrial-mediated apoptosis differently. FEBS Letters, 2005, 579, 6191-6198.	1.3	109
44	Nanomedicine: current status and future prospects. FASEB Journal, 2005, 19, 311-330.	0.2	1,732
45	Cellular Distribution of Nonionic Micelles. Science, 2004, 303, 626-628.	6.0	57
46	Synthetic polymers in 21st century therapeutics: the way forward â–¾. Drug Discovery Today, 2003, 8, 154-156.	3.2	5
47	Real-time evidence of surface modification at polystyrene lattices by poloxamine 908 in the presence of serum: in vivo conversion of macrophage-prone nanoparticles to stealth entities by poloxamine 908. FEBS Letters, 2003, 547, 177-182.	1.3	33
48	PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance. FEBS Letters, 2002, 532, 338-344.	1.3	131
49	Therapeutic synthetic polymers: a game of Russian roulette?. Drug Discovery Today, 2002, 7, 998-1001.	3.2	80
50	Volume-Activated Chloride Currents in HeLa Cells are Blocked by Tamoxifen But Not by a Membrane Impermeant Quaternary Analogue. Cellular Physiology and Biochemistry, 2001, 11, 99-104.	1.1	12
51	Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups. , 2001, 18, 1-8.		133
52	Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. Trends in Biotechnology, 2000, 18, 412-420.	4.9	351